Diabetic Cardiomyopathies
"Diabetic Cardiomyopathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Descriptor ID |
D058065
|
| MeSH Number(s) |
C14.280.238.235 C19.246.099.625
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Diabetic Cardiomyopathies".
Below are MeSH descriptors whose meaning is more specific than "Diabetic Cardiomyopathies".
This graph shows the total number of publications written about "Diabetic Cardiomyopathies" by people in this website by year, and whether "Diabetic Cardiomyopathies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 17 | 4 | 21 |
| 2018 | 21 | 2 | 23 |
| 2019 | 9 | 1 | 10 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Diabetic Cardiomyopathies" by people in Profiles.
-
Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors. J Fam Pract. 2021 07; 70(6S):S1-S6.
-
Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system. Cardiovasc Diabetol. 2021 04 27; 20(1):90.
-
COVID-19: Considerations of Diabetes and Cardiovascular Disease Management. J Diabetes Sci Technol. 2020 Jul; 14(4):723-724.
-
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019 11 05; 140(19):1569-1577.
-
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019 11 19; 140(21):1693-1702.
-
Up-regulation of microRNA-203 inhibits myocardial fibrosis and oxidative stress in mice with diabetic cardiomyopathy through the inhibition of PI3K/Akt signaling pathway via PIK3CA. Gene. 2019 Oct 05; 715:143995.
-
Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. Diabetes Care. 2019 09; 42(9):1792-1799.
-
Vitamin D downregulates key genes of diabetes complications in cardiomyocyte. J Cell Physiol. 2019 11; 234(11):21352-21358.
-
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.
-
Current Status and Challenges of NRF2 as a Potential Therapeutic Target for Diabetic Cardiomyopathy. Int Heart J. 2019 May 30; 60(3):512-520.